- Conditions
- Critical Limb Ischemia
- Interventions
- Open surgical revascularization, Endovascular revascularization
- Procedure · Device
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,843 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 144
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 102 more
Clinical trials in New Haven, Connecticut
This page shows live ClinicalTrials.gov search results for New Haven, Connecticut, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in New Haven
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Parkinson's Disease
- Interventions
- P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),, Placebo, P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),
- Drug
- Lead sponsor
- Pharma Two B Ltd.
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 21 more
- Conditions
- Ovarian Cancer
- Interventions
- Chemotherapy + avelumab followed by avelumab + talazoparib, Chemotherapy followed by talazoparib maintenance, Chemotherapy + bevacizumab followed by bevacizumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 26 more
- Conditions
- Advanced Solid Tumor, Recurrent Glioma
- Interventions
- PRT811
- Drug
- Lead sponsor
- Prelude Therapeutics Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 11
- States / cities
- Denver, Colorado • New Haven, Connecticut • Newark, Delaware + 8 more
- Conditions
- Endometrial Cancer
- Interventions
- sentinel lymph node detection, indocyanine green solution, isosulfan blue, sentinel lymph node biopsy
- Procedure · Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 85 Years · Female only
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Columbus, Ohio
- Conditions
- Aortic Valve Stenosis
- Interventions
- Medtronic Transcatheter Aortic Valve 2.0 Replacement System
- Device
- Lead sponsor
- Medtronic Cardiovascular
- Industry
- Eligibility
- Not listed
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 8
- States / cities
- New Haven, Connecticut • Kansas City, Kansas • Boston, Massachusetts + 4 more
- Conditions
- Voiding Disorders, Voiding Dysfunction
- Interventions
- Butterfly portable ultrasound device with bladder ultrasound images, Butterfly portable ultrasound device with abstract bladder images
- Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Type 2 Diabetes
- Interventions
- LY900014, Insulin Glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 30
- States / cities
- Concord, California • Escondido, California • Fresno, California + 25 more
- Conditions
- Amblyopia
- Interventions
- Gocheck Kids, Welch Allyn Spot Vision Screener, Physical Exam
- Device · Diagnostic Test
- Lead sponsor
- Yale University
- Other
- Eligibility
- 1 Year to 7 Years
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Skeletal Anomalies, Kidney Transplant; Complications
- Interventions
- measurements to evaluate metabolic bone disease, standard care
- Diagnostic Test
- Lead sponsor
- Yale University
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Osteoarthritis, Knee, Osteoarthritis, Hip
- Interventions
- Fasinumab, Diclofenac, Celecoxib, Matching placebo
- Drug · Other
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 71
- States / cities
- Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 63 more
- Conditions
- Induced; Birth
- Interventions
- Outpatient, Inpatient
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut